Search results for "Lung neoplasms"

showing 10 items of 432 documents

Pathological significance and prognostic value of surfactant protein D in cancer

2018

Surfactant protein D (SP-D) is a pattern recognition molecule belonging to the Collectin (collagen-containing C-type lectin) family that has pulmonary as well as extra-pulmonary existence. In the lungs, it is a well-established opsonin that can agglutinate a range of microbes, and enhance their clearance via phagocytosis and super-oxidative burst. It can interfere with allergen–IgE interaction and suppress basophil and mast cell activation. However, it is now becoming evident that SP-D is likely to be an innate immune surveillance molecule against tumor development. SP-D has been shown to induce apoptosis in sensitized eosinophils derived from allergic patients and a leukemic cell line via …

Male0301 basic medicineLung NeoplasmsDatasets as Topic0302 clinical medicineEpidermal growth factorNeoplasmsImmunology and AllergyRNA NeoplasmOriginal ResearchCancerOvarian NeoplasmsInnate immunitySurfactant protein DBioinformatics analysiPrognosisPulmonary Surfactant-Associated Protein DImmunohistochemistryTumor microenvironment030220 oncology & carcinogenesisAdenocarcinomaFemaleCancersBreast NeoplasmHumanlcsh:Immunologic diseases. AllergyPrognosiImmunologyBreast NeoplasmsBiology03 medical and health sciencesImmune systemBioinformatics analysisStomach NeoplasmsStomach NeoplasmBiomarkers TumormedicineHumansComputer SimulationLung cancerTumor microenvironmentOvarian NeoplasmComputational BiologySurfactant protein DCancermedicine.diseaseSurvival AnalysisLung NeoplasmImmune surveillance030104 developmental biologyCancer researchNeoplasmBioinformatics analysis; Cancers; Immune surveillance; Immunohistochemistry; Innate immunity; Surfactant protein D; Tumor microenvironment; Immunology and Allergy; Immunologylcsh:RC581-607Ovarian cancer
researchProduct

Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research

2019

Finnish hospital-integrated biobanks administer millions of formalin-fixed paraffin-embedded tissue samples collected within the clinical diagnostics. According to the Finnish Biobank Act, these samples can be coupled with patients’ clinical follow-up data and the data retrieved from national health registries. We collected a nationwide pulmonary carcinoid tumour series from Finnish biobanks to study prognostic factors as well as to explore how the number of tumours found in the Finnish biobanks corresponds to the number of tumours registered by the Finnish Cancer Registry (FCR). Finnish biobanks identified 88% of the tumours registered by the FCR and were able to deliver 63%. The main reas…

Male0301 basic medicineLung NeoplasmsProliferation indexbiopankitDiseaseNeuroendocrine tumorskeuhkosyöpäPulmonary carcinoidTumour tissue0302 clinical medicineRARERegistriesINDEXFinlandBiological Specimen BanksOUTCOMESrare cancerSURGICAL RESECTIONGeneral MedicineMiddle AgedPrognosisBiobank3. Good healthbiobank030220 oncology & carcinogenesisMediastinal lymph nodeSURVIVALOriginal ArticleFemaleBURDENpulmonary carcinoidAdultmedicine.medical_specialty3122 CancersCarcinoid TumorPathology and Forensic Medicine03 medical and health sciencesInternal medicinemedicineQUALITYHumansharvinaiset tauditMolecular BiologyBiobankbusiness.industryRare cancerennusteetCell Biologymedicine.diseaseCarcinoma NeuroendocrineCancer registryPulmonary carcinoid tumour030104 developmental biologyEXPERIENCEprognosis3111 BiomedicinebusinessNEUROENDOCRINE TUMORSVirchows Archiv
researchProduct

Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung …

2019

Aim: To assess outcomes in patients with advanced adenocarcinoma non-small-cell lung cancer who received nintedanib plus docetaxel after progression on prior chemotherapy followed by immune checkpoint inhibitor (ICI) therapy. Patients & methods: VARGADO is a prospective, noninterventional study. We describe initial data from a cohort of 22 patients who received nintedanib plus docetaxel after chemotherapy and ICI therapy. Results: Median progression-free survival with nintedanib plus docetaxel was 5.5 months (95% CI: 1.9–8.7 months). The objective response rate was 7/12 (58%) and the disease control rate was 10/12 (83%). Data for overall survival rate 12 months after the start of treat…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung Neoplasmsmedicine.medical_treatmentAdenocarcinoma of LungAntineoplastic AgentsDocetaxelDisease-Free Survival03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProspective StudiesLung cancerProspective cohort studyAdverse effectAgedChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDiscontinuationTreatment Outcome030104 developmental biologyOncologyDocetaxelchemistry030220 oncology & carcinogenesisFemaleNintedanibbusinessmedicine.drugFuture Oncology
researchProduct

Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells

2017

Several studies implicate that lung cancer progression is governed by the interaction between epidermal growth factor receptor (EGFR) signaling and protein kinase C (PKC) pathways. Combined the targeting of EGFR and PKC may have an additive or synergistic effects in lung cancer treatment. The aim of this study is to explore the potential utility by inhibiting these two pathways with the combination of erlotinib and chelerythrine chloride in non-small cell lung cancer (NSCLC) cell lines. The erlotinib-less sensitive cell lines SK-MES-1 and A549 were treated with erlotinib or chelerythrine by themselves or in combination with each other. The cell viability, clonogenic survival, cell migration…

Male0301 basic medicineOncologyCell signalingLung NeoplasmsCancer Treatmentlcsh:MedicineApoptosisMice SCIDSignal transductionLung and Intrathoracic TumorsMicechemistry.chemical_compoundMice Inbred NODCarcinoma Non-Small-Cell LungMedicine and Health SciencesEpidermal growth factor receptorPhosphorylationlcsh:ScienceErlotinib HydrochlorideMultidisciplinaryCell DeathbiologyPharmaceuticsChemistrySignaling cascadesFlow CytometryErbB ReceptorsCell MotilityOncologyCell ProcessesDrug Therapy CombinationErlotinibSignal transductionEGFR signalingResearch Articlemedicine.drugmedicine.medical_specialtyMAPK signaling cascadesCell MigrationErlotinib Hydrochloride03 medical and health sciencesDrug TherapyCell Line TumorInternal medicinemedicineAnimalsHumansViability assayLung cancerBenzophenanthridineslcsh:RCancers and NeoplasmsBiology and Life SciencesCell Biologymedicine.diseaseXenograft Model Antitumor AssaysNon-Small Cell Lung Cancerrespiratory tract diseases030104 developmental biologyChelerythrineApoptosisCancer researchbiology.proteinlcsh:QDevelopmental BiologyPLOS ONE
researchProduct

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with …

2016

// Giuseppe Bronte 1, * , Tindara Franchina 2, * , Massimiliano Alu 3, * , Giovanni Sortino 1 , Claudia Celesia 1 , Francesco Passiglia 1 , Giuseppina Savio 3 , Agata Laudani 3 , Alessandro Russo 2 , Antonio Picone 2 , Sergio Rizzo 1 , Michele De Tursi 4 , Elisabetta Gambale 4 , Viviana Bazan 1 , Clara Natoli 4 , Livio Blasi 3 , Vincenzo Adamo 2 , Antonio Russo 1 1 Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy 3 Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy 4 Department of Medical, Oral and Biotechnological …

Male0301 basic medicineOncologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classEGFRTyrosine kinase inhibitorKaplan-Meier EstimateTyrosine-kinase inhibitorErlotinib Hydrochloride03 medical and health sciences0302 clinical medicineGefitinibCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansChemotherapyErlotinib HydrochlorideLung cancerProtein Kinase InhibitorsChemotherapy EGFR Non-small-cell lung cancer Tyrosine kinase inhibitor OncologyAgedRetrospective StudiesAged 80 and overPerformance statusbusiness.industryChemotherapy; EGFR; Non-small-cell lung cancer; Tyrosine kinase inhibitor; OncologyGefitinibRetrospective cohort studyMiddle Agedmedicine.diseaserespiratory tract diseasesSurgeryErbB ReceptorsClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationQuinazolinesFemaleErlotinibbusinessNon-small-cell lung cancerResearch Papermedicine.drug
researchProduct

CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squ…

2021

Abstract Background Patients with head and neck squamous cell carcinoma (HNSCC) can develop lung squamous cell carcinoma (LuSCC), which could be the second primary tumor or HNSCC metastasis. Morphologically it is difficult to distinguish metastatic HNSCC from a second primary tumor which presents a significant diagnostic challenge. Differentiation of those two malignancies is important because the recommended treatments for metastatic HNSCC and primary LuSCC differ significantly. We investigated if the quantification of the promotor methylation status in HNSCC and LuSCC differs. Methods Primary HNSCC (N = 36) and LuSCC (N = 17) were included in this study. Methylation status in the ASC/TMS1…

Male0301 basic medicinePathologyLung NeoplasmsHNSCCEpigenesis GeneticMetastasis0302 clinical medicinePromoter Regions GeneticLungDiagnostic biomarkerPYCARDGeneral MedicineMethylationMiddle AgedGene Expression Regulation NeoplasticBisulfiteCpG siteHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellSecond primary tumorFemalelcsh:RB1-214Adultmedicine.medical_specialtyHistologyShort ReportBiologyMethylationPathology and Forensic Medicine03 medical and health sciencesCpG ; diagnostic biomarker ; HNSCC ; lung ; methylation ; second primary tumorCpGClinical Medical Scienceslcsh:PathologymedicineHumansGeneAdaptor Proteins Signal TransducingAgedSquamous Cell Carcinoma of Head and NeckPromotermedicine.diseaseHead and neck squamous-cell carcinomastomatognathic diseases030104 developmental biologyMyeloid Differentiation Factor 88Cancer researchCpG IslandsDiagnostic Pathology
researchProduct

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

2019

Abstract Introduction Quality of life (QoL) of comorbid patients with pulmonary malignancies is a key issue in considering fractionated stereotactic body radiotherapy (SBRT) indication. This study investigates the early impact of SBRT on QoL. Methods One hundred patients with pulmonary lesions were treated with SBRT from February 2011 to December 2014 within the prospective, monocenter, phase II STRIPE trial. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core module (EORTC QLQ-C30) and the QLQ-LC13 lung cancer-specific questionnaire were used to evaluate QoL before, 2 and 7 weeks after SBRT, then every 3 months for 2 years. We report on the ana…

Male0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyLung NeoplasmsHealth StatusRadiosurgeryEmotional function03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesAgedLungbusiness.industryCancerPrognosismedicine.diseasehumanitiesKarnofsky index030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCharlson comorbidity indexQuality of LifeFemaleDose Fractionation RadiationbusinessStereotactic body radiotherapyFollow-Up StudiesJournal of Thoracic Oncology
researchProduct

3D CT scan for perioperative identification of anatomical variations of lungs.

2016

Aim: The aim of this study is to investigate anatomical lung variations and vascular patterns using volumetric 3D computed tomography (CT) representations. Methods & results: We considered 24 major thoracic surgery performed in our ward. In these, we discovered some interesting anatomical variations of the main pulmonary fissures. These findings were not visible on the plain x-ray or during routine examination of a preoperative CT scan. After re-examination of 3D CT scan reconstruction the anatomical variations were detected. Discussion: General thoracic surgeons must familiarize themselves with anatomical variations in lungs. 3D images may aid the general thoracic surgeon in performin…

MaleCT reconstructionCancer Researchmedicine.medical_specialtyLung NeoplasmsCT reconstruction; anatomic variations; lung surgeryComputed tomography030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineImaging Three-DimensionalImage Interpretation Computer-Assistedmedicine3d ct scanImage Processing Computer-AssistedHumansLung surgeryanatomic variationsPerioperative PeriodPneumonectomyAgedAged 80 and overLungmedicine.diagnostic_testThoracic surgeonbusiness.industryThoracic Surgery Video-AssistedGeneral MedicinePerioperativeMiddle Agedlung surgerymedicine.anatomical_structureOncologyCardiothoracic surgery030220 oncology & carcinogenesisFemaleRadiologybusinessTomography X-Ray ComputedCt reconstructionFuture oncology (London, England)
researchProduct

Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk

2019

miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major …

MaleCancer ResearchCell typeLung NeoplasmsCarcinogenesisNeutrophilsMacrophageMice SCIDBiologymedicine.disease_causeMolecular Cancer Biology03 medical and health sciencesParacrine signallingMice0302 clinical medicineImmune systemCell Line TumormicroRNAmedicineTobacco SmokingAnimalsHumansCirculating MicroRNALung cancerLungCarcinogenesiTumor microenvironmentmicroRNAAnimalMacrophagesGene Expression ProfilingNeutrophilSTAT4 Transcription Factormedicine.diseasemicroenvironmentXenograft Model Antitumor Assays3. Good healthGene Expression Regulation NeoplasticLung NeoplasmMicroRNAslung cancerOncology030220 oncology & carcinogenesisCancer cellCancer researchFemaleTumor EscapeCarcinogenesisHuman
researchProduct

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

2018

Abstract Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naive patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to Februa…

MaleCancer ResearchLung NeoplasmsColorectal cancerFOLFIRINOXGastrointestinal DiseasesSynchronous metastasesLeucovorinKaplan-Meier EstimateInduction0302 clinical medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsRectal cancerINDUCTION TREATMENTFatigueResponse rate (survey)medicine.diagnostic_testLiver NeoplasmsRemission InductionMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingProgression-Free Survival3. Good healthOxaliplatinFOLFIRINOXTreatment OutcomeOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleRadiologyFluorouracilAdultmedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaIrinotecan03 medical and health sciencesmedicineHumansParesthesiaAgedPerformance statusbusiness.industryRectal NeoplasmsMagnetic resonance imagingmedicine.diseaseHematologic DiseasesConfidence intervalLocal controlbusinessTomography X-Ray ComputedFollow-Up Studies
researchProduct